
New American Therapeutics, Inc.: A specialty pharmaceutical firm focused on improving lives with cardiovascular solutions.
New American Therapeutics, Inc. is a privately held specialty pharmaceutical company founded in Parsippany, New Jersey. The company's core mission is to improve patients' lives by acquiring, marketing, and developing pharmaceutical products in select therapeutic areas, with a particular focus on cardiovascular health. Their portfolio includes a lead product aimed at addressing cardiovascular conditions, reflecting their commitment to enhancing patient outcomes in this critical medical field.
Notable figures affiliated with New American Therapeutics include experienced leaders in the pharmaceutical industry, though specific names are not publicly highlighted. The company has successfully brought its lead cardiovascular product to market, demonstrating its capability to navigate the complexities of pharmaceutical development and commercialization. Overall, New American Therapeutics has made a significant impact by providing specialized treatments that address unmet medical needs in the cardiovascular sector.

NeuroTherapeutics Pharma

Cardurion Pharmaceuticals

Cortria

Theracos
theracos.com

Novita Therapeutics

Anexon

Novatarg
novatarg.org

HDL Therapeutics

Therapyx
therapyxinc.com

Amerigen Pharmaceuticals
amerigenpharma.com

TheraVasc

Chase Therapeutics

Amneal Pharmaceuticals
amneal.com

Tenax Therapeutics
tenaxthera.com

NanoPharmaceuticals
Companies similar to New American Therapeutics include NeuroTherapeutics Pharma, Cardurion Pharmaceuticals, Cortria and Theracos.
New American Therapeutics was founded in 2010.
New American Therapeutics' headquarters is located in Roseland, NJ, US.
New American Therapeutics' most recent funding round was for $53M (USD) in September 2010.
As of Sep 1, 2010, New American Therapeutics has raised a total of $53M (USD).
New American Therapeutics has 5 employees as of Feb 4, 2024.